There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

Despite the approval of numerous antibody-drug conjugates (ADCs), their therapeutic index remains limited by off-target toxicity resulting from linker instability. To address this challenge, the ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

OS Therapies Inc (NYSE-A:OSTX) shares jumped 12.4% following favorable feedback from the FDA regarding its OST-HER2 treatment ...

A new drug, camizestrant, shows promise in delaying progression of aggressive breast cancer. This treatment uses blood ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.